Abstract
Nitric oxide (NO)-releasing non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have a safer profile and additional anti-inflammatory and immuno-modulatory properties compared to parent compounds. Preventive treatment of experimental autoimmune encephalomyelitis (EAE)-induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55-with the NO-releasing derivative of flurbiprofen HCT1026 delayed disease onset and significantly decreased disease severity. HCT1026 treatment was associated to (i) decreased mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells; (ii) decreased ability of encephalitogenic T cells to proliferate; (iii) reduced number of central nervous system (CNS)-infiltrating T cells; (iv) decreased axonal loss and demyelination; (v) increased CD4+ CD69 - CD25+ regulatory T cells in the spleen.
Original language | English |
---|---|
Pages (from-to) | 10-19 |
Number of pages | 10 |
Journal | Journal of Neuroimmunology |
Volume | 150 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - May 2004 |
Keywords
- Caspase-1
- EAE
- IFN-γ
- IL-10k/o
- Nitric oxide
- NSAID
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology